Transglutaminases and neurodegeneration.

Transglutaminases and neurodegeneration.
复制标题

DOI:
10.1111/j.1471-4159.2009.05843.x
复制
发表时间:
2009-05
影响因子:
4.7
通讯作者:
Cooper AJ
Cooper AJ
中科院分区:
医学2区
文献类型:
--
作者:
Jeitner TM;Pinto JT;Krasnikov BF;Horswill M;Cooper AJ

文献摘要

参考文献

被引文献

相似文献

谷氨酰胺转胺酶(TGs)是Ca2+依赖性酶,催化谷氨酰基(Q)残基的各种修饰。在大脑中,这些修饰包括许多含胺化合物的共价附着,包括赖氨酸(K)残基和多胺,它们要么调节酶活性,要么将TG底物附着在生物基质上。异常的TG活性被认为与阿尔茨海默病、帕金森病、亨廷顿病和核上性麻痹有关。设计干扰TG活性的策略在亨廷顿和帕金森病的动物模型中有一定的益处。以下综述总结了TGs在神经退行性疾病中的作用,并讨论了选择性抑制剂作为这些疾病治疗药物的可能性。
Transglutaminases (TGs) are Ca2+-dependent enzymes that catalyze a variety of modifications of glutaminyl (Q) residues. In the brain, these modifications include the covalent attachment of a number of amine-bearing compounds, including lysyl (K) residues and polyamines, which serve to either regulate enzyme activity or attach the TG substrates to biological matrices. Aberrant TG activity is thought to contribute to Alzheimer disease, Parkinson disease, Huntington disease, and supranuclear palsy. Strategies designed to interfere with TG activity have some benefit in animal models of Huntington and Parkinson diseases. The following review summarizes the involvement of TGs in neurodegenerative diseases and discusses the possible use of selective inhibitors as therapeutic agents in these diseases.
DOI: 10.1016/j.febslet.2004.10.074
发表时间: 2004-12-03
期刊: FEBS LETTERS
影响因子: 3.5
作者:
Campisi, A;Caccamo, D;Ientile, R
通讯作者: Ientile, R
DOI: 10.1016/j.pep.2003.10.003
发表时间: 2004-02-01
影响因子: 1.6
作者:
Gillet, SMFG;Chica, RA;Pelletier, JN
通讯作者: Pelletier, JN
DOI: 10.1016/0896-6273(95)90346-1
发表时间: 1995-05-01
期刊: NEURON
影响因子: 16.2
作者:
DIFIGLIA, M;SAPP, E;ARONIN, N
通讯作者: ARONIN, N